Significance of ST2 in the Early Diagnosis and Treatment of Graft-Versus-Host Disease--Review.
10.7534/j.issn.1009-2137.2016.01.060
- Author:
Run-Qing LU
1
;
Rong GUO
2
Author Information
1. Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
2. Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail: gh7311@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Autoimmune Diseases;
Biomarkers;
Early Diagnosis;
Graft vs Host Disease;
diagnosis;
therapy;
Hematopoietic Stem Cell Transplantation;
adverse effects;
Humans;
Receptors, Interleukin-1;
metabolism;
Transplantation, Homologous
- From:
Journal of Experimental Hematology
2016;24(1):307-310
- CountryChina
- Language:Chinese
-
Abstract:
Graft-versus-host disease (GVHD) is a major complication of allo-hematopoietic stem cell transplantation. It is reported that IL-2R, TNFR1, elafin (for skin GVHD) and REG-3α (for gastrointestinal GVHD) can be used in the early diagnosis of acute GVHD, but they cannot predict the response to therapy independently. Therefore, it is urgent to find a biomarker to predict GVHD and glucocorticoid resistance. ST2 is a member of IL-1 receptor family and specially binds to IL-33. Researchers have found that higher ST2 level is associated with increased GVHD risk, glucocorticoid resistance and transplantation-related mortality. This review focuses on the structure, function, signal transduction pathway of ST2/IL-33, and its roles in diagnosis and treatment of autoimmune diseases and GVHD.
